Katja Christina Weisel

机构：Universität Hamburg, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg · ORCID：0000-0001-9422-6614

发表论文 825 篇 · 总被引 27320 次 · h-index 73

代表论文

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial (2026 · Nature Medicine · 被引 6)
A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma (2026 · Blood Cancer Journal)
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis (2026 · Leukemia)
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial (2026 · Nature Medicine)
Supplementary Table S4 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy (2026)
Supplementary Table S11 from Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy (2026)